Propylthiouracil-induced autoimmune syndromes: 11 case report

Area of Science:

• Rheumatology
• Endocrinology
• Internal Medicine

Background:

• Propylthiouracil (PTU) is a medication used to treat hyperthyroidism.
• Autoimmune syndromes are a potential adverse effect of PTU treatment.
• Distinguishing between different PTU-induced autoimmune conditions is crucial for patient management.

Observation:

• This study reports on 11 cases of PTU-induced autoimmune syndromes.
• Seven patients presented with vasculitis, and four with lupus.
• Patients with PTU-induced vasculitis were older and had longer PTU treatment durations compared to those with lupus.

Findings:

• PTU-induced vasculitis and lupus exhibit distinct clinical features and outcomes.
• Anti-neutrophil cytoplasmic antibodies (P-ANCA) were prevalent in vasculitis but also observed in lupus.
• Antinuclear antibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) antibodies were more common in lupus.
• Renal and pulmonary involvement differed between the two conditions.
• Most patients required corticosteroids or immunosuppressive therapy.

Implications:

• Early recognition of PTU-induced autoimmune syndromes is essential.
• Understanding the differences between PTU-induced lupus and vasculitis aids in diagnosis and treatment.
• Further research into the mechanisms and management of these conditions is warranted.